Emergent BioSolutions Inc. (EBS)

Market Cap	634.97M
Revenue (ttm)	788.90M
Net Income (ttm)	75.90M
Shares Out	52.52M
EPS (ttm)	1.35
PE Ratio	8.95
Forward PE	4.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,263,788
Open	11.54
Previous Close	11.50
Day's Range	11.54 - 12.58
52-Week Range	4.02 - 14.06
Beta	2.30
Analysts	Strong Buy
Price Target	15.00 (+24.07%)
Earnings Date	Mar 2, 2026

About EBS

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 15, 2006
• Employees: 900
• Stock Exchange: NYSE
• Ticker Symbol: EBS
• Website: https://www.emergentbiosolutions.com

Financial Performance

In 2024, Emergent BioSolutions's revenue was $1.04 billion, a decrease of -0.54% compared to the previous year's $1.05 billion. Losses were -$190.60 million, -74.94% less than in 2023.

Analyst Summary

According to one analyst, the rating for EBS stock is "Strong Buy" and the 12-month stock price target is $15.0.

Price Target

$15.0

(24.07% upside)

Analyst Consensus: Strong Buy